Fig. 4: In vivo engagement of αvβ6 via the inhaled route in a fibrotic lung. | Nature Communications

Fig. 4: In vivo engagement of αvβ6 via the inhaled route in a fibrotic lung.

From: Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis

Fig. 4

a Effect of GSK3008348 on the binding of the selective αvβ6 integrin nanoSPECT-CT ligand [111In]A20FMDV2 in naive (saline treated) and bleomycin-treated mice following i.n. dosing (mean ± SEM; n = 5–6 animals per group; ANOVA with Fisher’s LSD post test comparisons versus corresponding vehicle or IgG2A control or between active groups). b Representative axial SPECT/CT scans of thorax detected binding of [111In]A20FMDV2 in lungs of naive (saline treated) or bleomycin-treated mice receiving vehicle (i.n. saline) or GSK3008348 (1 mg/kg) from the study shown in panel a. c Dose-dependent effect of GSK3008348 on the binding of the selective αvβ6 integrin nanoSPECT-CT ligand [111In]A20FMDV2 in bleomycin-treated mice following i.n. dosing (mean ± SEM; n = 6–12 animals per group; ANOVA with Fisher’s LSD post test comparisons versus vehicle i.n. control). Representative axial SPECT/CT scans of thorax detected binding of [111In]A20FMDV2 also shown. Source data are provided as a Source Data file.

Back to article page